- Exchange: Copenhagen
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Novo Nordisk A/S
+ Add to WatchlistNOVOB:DC
995.500 DKK 0.500 0.05%As of 03:50:25 ET on 05/21/2013.
Snapshot for Novo Nordisk A/S (NOVOB)
| Open: | 995.000 | Day's Range: | 992.500 - 997.000 | Volume: | 458,062 |
|---|---|---|---|---|---|
| Previous Close: | 995.000 | 52wk Range: | 770.000 - 1,100.000 | 1-Yr Rtn: | +19.85% |
Key Statistics for NOVOB
| Current P/E Ratio (ttm) | 23.6885 |
|---|---|
| Estimated P/E(12/2013) | 21.2448 |
| Relative P/E vs. KFX | 1.0861 |
| Earnings Per Share (DKK) (ttm) | 41.7713 |
| Est. EPS (DKK) (12/2013) | 46.5760 |
| Est. PEG Ratio | 1.3655 |
| Market Cap (M DKK) | 544,225.00 |
| Shares Outstanding (M) | 442.51 |
| 30 Day Average Volume | 674,111 |
| Price/Book (mrq) | 15.7892 |
| Price/Sale (ttm) | 6.7130 |
| Dividend Indicated Gross Yield | 1.82% |
| Cash Dividend (DKK) | 18.0000 |
| Last Dividend | 03/21/2013 |
| 5 Year Dividend Growth | 31.95% |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NOVOB
Company Profile & Key Executives for NOVOB
Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.
| Lars Rebien SorensenPresident/CEO | Jesper BrandgaardExec VP/CFO |
| Kaare SchultzExec VP/COO | Mads Krogsgaard ThomsenExec VP/Chief Science Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NOVOB News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page